Olivier Danos Ph.D.
Net Worth

Last updated: 15 Apr 2019

What is Olivier Danos Ph.D. net worth?

The estimated net worth of Dr. Olivier Danos Ph.D. is at least $5,714,519 as of 15 Apr 2019. He owns shares worth $62,999 as insider, has earned $1,284,500 from insider trading and has received compensation worth at least $4,367,020 in null.

What is the salary of Olivier Danos Ph.D.?

Dr. Olivier Danos Ph.D. salary is $623,860 per year as Senior Vice President & Chief Scientific Officer in null.

How old is Olivier Danos Ph.D.?

Dr. Olivier Danos Ph.D. is 67 years old, born in 1958.

What stocks does Olivier Danos Ph.D. currently own?

As insider, Dr. Olivier Danos Ph.D. owns shares in one company:

Company	Title	Shares	Price per share	Total value
(RGNX)	Senior Vice President & Chief Scientific Officer	7,500	$8.4	$62,999

What does do?

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX

$8.4

Olivier Danos Ph.D. insider trading

Dr. Olivier Danos Ph.D. has made 3 insider trades between 2018-2019, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 20,000 units of RGNX stock on 8 Oct 2018. As of 15 Apr 2019 he still owns at least 7,500 units of RGNX stock.

Transaction	Date	Security	Shares	Price per share	Total value
Option	15 Apr 2019	Common Stock	2,000	N/A	N/A
Sale	15 Apr 2019	Common Stock	2,000	N/A	N/A
Option	15 Apr 2019	Stock Option (Right to Buy)	2,000	N/A	N/A
Option	12 Mar 2019	Stock Option (Right to Buy)	5,000	N/A	N/A
Option	12 Mar 2019	Common Stock	5,000	N/A	N/A
Option	30 Nov 2018	Common Stock	1,500	N/A	N/A
Option	30 Nov 2018	Stock Option (Right to Buy)	1,500	N/A	N/A
Option	8 Oct 2018	Stock Option (Right to Buy)	20,000	N/A	N/A
Sale	8 Oct 2018	Common Stock	20,000	$64.23	$1,284,500
Option	8 Oct 2018	Common Stock	20,000	N/A	N/A
Sale	8 Oct 2018	Common Stock	20,000	N/A	N/A

key executives

executives and other stock owners filed with the SEC:

Dr. Olivier Danos Ph.D. (67) Senior Vice President & Chief Scientific Officer
Mr. Curran M. Simpson M.S. (63) Senior Vice President and Chief Operations & Technology Officer
Mr. Kenneth T. Mills (50) Pres, Chief Executive Officer & Director
Mr. Patrick J. Christmas II (54) Senior Vice President & Chief Legal Officer
Mr. Vittal K. Vasista (57) Senior Vice President & Chief Financial Officer

Olivier Danos Ph.D. Net Worth